

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gosselin *et al.*

Serial No.: 10/022,276

Filed: December 14, 2001

Art Unit: 1623

Patent No.: 6,569,837

Examiner: Lawrence E. Crane

Issued: May 27, 2003

For: β -L-2'-DEOXY-NUCLEOSIDES FOR THE
TREATMENT OF HEPATITIS B

Attorney Docket No: 06171.105080
(IDX 1000 CON1)
(New Docket No. 11874-030-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

IDENIX PHARMACEUTICALS, INC. (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number **20583**

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

☐

Applicant/Inventor

☒

Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

STATEMENT UNDER 37 C.F.R. 3.73(b)

IDENIX PHARMACEUTICALS, INC. states that it is, along with Centre National De La Recherche Scientifique ("CNRS") and L'Universite Montpellier II ("UMII"), is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:

1. Inventors Gilles Gosselin and Jean-Louis Imbach assigned their interest to CNRS and inventor Martin L. Bryant assigned his interest to Novirio Pharmaceuticals Limited in the parent patent application U.S. Patent Application No. 09/371,747, filed August 10, 1999, now U.S. Patent No. 6,395,716, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on September 27, 1999, at Reel 010271, Frame 0725.
2. CNRS assigned its interest received from inventor Jean-Louis Imbach to UMII in the parent patent application U.S. Patent Application No. 09/371,747, filed August 10, 1999, now U.S. Patent No. 6,395,716, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on June 3, 2002, at Reel 012937, Frame 0346.
3. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.


The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: IDENIX PHARMACEUTICALS, INC.

Date:

11/19/07

Signature:



Typed Name:

Jean-Pierre Sommadossi

Position/Title:

CEO

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gosselin *et al.*

Serial No.: 10/022,276

Filed: December 14, 2001

Art Unit: 1623

Patent No.: 6,569,837

Examiner: Lawrence E. Crane

Issued: May 27, 2003

For: β -L-2'-DEOXY-NUCLEOSIDES FOR THE
TREATMENT OF HEPATITIS B

Attorney Docket No: 06171.105080
(IDX 1000 CON1)
(New Docket No. 11874-030-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

L'UNIVERSITE MONTPELLIER II (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number **20583**

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

☐

Applicant/Inventor

☒

Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

STATEMENT UNDER 37 C.F.R. 3.73(b)

L'UNIVERSITE MONTPELLIER II ("UMII") states that it is, along with Idenix Pharmaceuticals, Inc. and Centre National De La Recherche Scientifique ("CNRS"), is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:

1. Inventors Gilles Gosselin and Jean-Louis Imbach assigned their interest to CNRS and inventor Martin L. Bryant assigned his interest to Novirio Pharmaceuticals Limited in the parent patent application U.S. Patent Application No. 09/371,747, filed August 10, 1999, now U.S. Patent No. 6,395,716, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on September 27, 1999, at Reel 010271, Frame 0725.
2. CNRS assigned its interest received from inventor Jean-Louis Imbach to UMII in the parent patent application U.S. Patent Application No. 09/371,747, filed August 10, 1999, now U.S. Patent No. 6,395,716, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on June 3, 2002, at Reel 012937, Frame 0346.
3. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.


The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: L'UNIVERSITE MONTPELLIER II

Date: NOVEMBER 15TH, 2007 Signature: _____

Typed Name: JEAN-LOUIS CUIR

Position/Title: PRESIDENT



IDENIX
DI 85256-02
IDX 1000

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gosselin *et al.*

Serial No.: 10/022,276

Filed: December 14, 2001

Art Unit: 1623

Patent No.: 6,569,837

Examiner: Lawrence E. Crane

Issued: May 27, 2003

For: β -L-2'-DEOXY-NUCLEOSIDES FOR THE
TREATMENT OF HEPATITIS B

Attorney Docket No: 06171.105080
(IDX 1000 CON1)
(New Docket No. 11874-030-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (assignee) hereby
revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number **20583**

to prosecute the application identified above, and to transact all business in the United States
Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

☐

Applicant/Inventor

☒

Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

IDENIX
DI 85256-02
IDX 1000

STATEMENT UNDER 37 C.F.R. 3.73(b)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ("CNRS") states that it is, along with Idenix Pharmaceuticals, Inc. and L'Universite Montpellier II ("UMII"), is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:

1. Inventors Gilles Gosselin and Jean-Louis Imbach assigned their interest to CNRS and inventor Martin L. Bryant assigned his interest to Novirio Pharmaceuticals Limited in the parent patent application U.S. Patent Application No. 09/371,747, filed August 10, 1999, now U.S. Patent No. 6,395,716, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on September 27, 1999, at Reel 010271, Frame 0725.
2. CNRS assigned its interest received from inventor Jean-Louis Imbach to UMII in the parent patent application U.S. Patent Application No. 09/371,747, filed August 10, 1999, now U.S. Patent No. 6,395,716, and continuations, divisionals and continuations-in-part thereof, which was recorded in the United States Patent and Trademark Office on June 3, 2002, at Reel 012937, Frame 0346.
3. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Date: 28 NOV. 2007

Signature: _____

Typed Name: _____

Position/Title: _____

Directeur de la Politique Industrielle

Marc J. LEDOUX

Directeur du Service du Transfert de
Technologies

Frédéric FOUBERT

